



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 53066

**Title:** Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma

**Reviewer's code:** 00054672

**Position:** Editorial Board

**Academic degree:** FEBG, MD, PhD

**Professional title:** Associate Professor

**Reviewer's country:** Croatia

**Author's country:** Japan

**Manuscript submission date:** 2019-12-20

**Reviewer chosen by:** Jin-Zhou Tang

**Reviewer accepted review:** 2020-01-10 18:04

**Reviewer performed review:** 2020-01-12 08:11

**Review time:** 1 Day and 14 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

Hepatocellular carcinoma (HCC) is a potentially curative tumor if detected early. Biological markers for HCC, play an important role in the process of screening, detection and prognosis. Current markers are insufficient in the aforementioned, and therefore the detection and evaluation of new markers is of paramount importance. The study by Yamashita et al. investigates the diagnostic value of serum preneoplastic antigen (PNA) for HCC in HCV patients. It is a well designed study with a control arm and three HCV arms (hepatitis, cirrhosis and HCC). The results indicate that it can be a useful marker for HCC, especially in a specific subset of HCC patients. The manuscript is well-prepared, information is clearly and concisely described and discussed in good English. I would suggest omitting comments from the Results; comments, explanations and speculations should be reserved for the Discussion.

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](https://www.wjgnet.com)